Title(s):
Professor of Oncology
Professor of Medicine
Professor of Pathology
Professor of Radiation Oncology and Molecular Radiation Sciences
Professor of Urology
Professor of Medicine
Professor of Pathology
Professor of Radiation Oncology and Molecular Radiation Sciences
Professor of Urology
Director, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Marion I. Knott Professor of Oncology
Marion I. Knott Professor of Oncology
Appointment Phone:
410-955-8964
Primary Location:
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Expertise:
General Internal Medicine, Prostate Cancer
Education and Experience
Training
- Johns Hopkins University School of Medicine (Baltimore MD)/ (1987)
Residencies
- The Johns Hopkins Hospital (Baltimore MD)/ Medicine (1989)
Fellowships
- The Johns Hopkins Hospital (Baltimore MD)/ Oncology (1991)
Locations
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N. Broadway
Baltimore, MD 21231
Phone: 410-955-8410
Appointment Phone: 410-955-8964
Location Map
Department / Division
- Oncology
Centers/Institutes
Centers / Institutes
- Sidney Kimmel Comprehensive Cancer Center
Bio
Physician Title
Director, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Marion I. Knott Professor of Oncology
Marion I. Knott Professor of Oncology
Expertise
- General Internal Medicine
- Prostate Cancer
Research
Research and Publications
Journal Citations
Nelson, W.G.; Saad, F.; Debruyne, F.; Eisenberger, M.; Fourcade, R.; Frenkel, E.; Kantoff, P.; Kumon, H.; Nasu, Y.; Oudard, S.; Wirth, M. New Therapeutic Targets and Treatments for Metastatic Prostate Cancer. Prostate Cancer. Paris: Health Publications; 2006.
Palapattu, G.S.; Meeker, A.; Harris, T.; Collector, M.I.; Sharkis, S.J.; DeMarzo, A.M.; Warlick, C.; Drake, C.G.; Nelson, W.G. Epithelial architectural destruction is necessary for bone marrow derived cell contribution to regenerating prostate epithelium. J Urol. 2006 Aug;176(2):813-818.
Rogers, C.G.; Gonzalgo, M.L.; Yan, G.; Bastian, P.J.; Chan, D.Y.; Nelson, W.G.; Pavlovich, C.P. High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection. J Urol. 2006 Nov;176(5):2280-2284.
Simons, J.W.; Carducci, M.A.; Mikhak, B.; Lim, M.; Biedrzycki, B.; Borellini, F.; Clift, S.M.; Hege, K.M.; Ando, D.G.; Piantadosi, S.; Mulligan, R.; Nelson, W.G. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3394-3401.
Sutcliffe, S.; Zenilman, J.M.; Ghanem, K.G.; Jadack, R.A.; Sokoll, L.J.; Elliott, D.J.; Nelson, W.G.; De Marzo, A.M.; Cole, S.R.; Isaacs, W.B.; Platz, E.A. Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. J Urol. 2006 May;175(5):1937-1942.
Yegnasubramanian, S.; Lin, X.; Haffner, M.C.; DeMarzo, A.M.; Nelson, W.G. Combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylation. Nucleic Acids Res. 2006;34(3):e19.
Agoston, A.T.; Argani, P.; De Marzo, A.M.; Hicks, J.L.; Nelson, W.G. Retinoblastoma pathway dysregulation causes DNA methyltransferase 1 overexpression in cancer via MAD2-mediated inhibition of the anaphase-promoting complex. Am J Pathol. 2007 May;170(5):1585-1593.
Bastian, P.J.; Palapattu, G.S.; Yegnasubramanian, S.; Lin, X.; Rogers, C.G.; Mangold, L.A.; Trock, B.; Eisenberger, M.; Partin, A.W.; Nelson, W.G. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5361-5367.
De Marzo, A.M.; Nakai, Y.; Nelson, W.G. Inflammation, atrophy, and prostate carcinogenesis. Urol Oncol. 2007 Sep-Oct;25(5):398-400.
De Marzo, A.M.; Platz, E.A.; Sutcliffe, S.; Xu, J.; Gronberg, H.; Drake, C.G.; Nakai, Y.; Isaacs, W.B.; Nelson, W.G. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007 Apr;7(4):256-269.
Nakai, Y.; Nelson, W.G.; De Marzo, A.M. The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. Cancer Res. 2007 Feb 1;67(3):1378-1384.
Nelson, W.G. Prostate cancer prevention. Curr Opin Urol. 2007 May;17(3):157-167.
Nelson, W.G.; Yegnasubramanian, S.; Agoston, A.T.; Bastian, P.J.; Lee, B.H.; Nakayama, M.; De Marzo, A.M. Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci. 2007;12:4254-4266.
Rohrmann, S.; Nelson, W.G.; Rifai, N.; Brown, T.R.; Dobs, A.; Kanarek, N.; Yager, J.D.; Platz, E.A. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab. 2007 Jul;92(7):2519-2525.
Rohrmann, S.; Nelson, W.G.; Rifai, N.; Kanarek, N.; Basaria, S.; Tsilidis, K.K.; Smit, E.; Giovannucci, E.; Platz, E.A. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III). Urology. 2007 Apr;69(4):708-713.
Selvin, E.; Feinleib, M.; Zhang, L.; Rohrmann, S.; Rifai, N.; Nelson, W.G.; Dobs, A.; Basaria, S.; Golden, S.H.; Platz, E.A. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care. 2007 Feb;30(2):234-238.
Small, E.J.; Sacks, N.; Nemunaitis, J.; Urba, W.J.; Dula, E.; Centeno, A.S.; Nelson, W.G.; Ando, D.; Howard, C.; Borellini, F.; Nguyen, M.; Hege, K.; Simons, J.W. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res. 2007 Jul 1;13(13):3883-3891.
Sutcliffe, S.; Rohrmann, S.; Giovannucci, E.; Nelson, K.E.; De Marzo, A.M.; Isaacs, W.B.; Nelson, W.G.; Platz, E.A. Viral infections and lower urinary tract symptoms in the third national health and nutrition examination survey. J Urol. 2007 Nov;178(5):2181-2185.
Bastian, P.J.; Ellinger, J.; von Rucker, A.; Muller, S.C.; Yegnasubramanian, S.; Nelson, W.G.; Stief, C.G. [CpG island hypermethylation of the DNA. Perspectives of a molecular biomarker for prostate cancer]. Der Urologe Ausg. 2008 Sep;47(9):1205-1207.
Bastian, P.J.; Palapattu, G.S.; Yegnasubramanian, S.; Rogers, C.G.; Lin, X.; Mangold, L.A.; Trock, B.; Eisenberger, M.A.; Partin, A.W.; Nelson, W.G. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol. 2008 Feb;179(2):529-534; discussion 534-525.
Cheever, M.A.; Schlom, J.; Weiner, L.M.; Lyerly, H.K.; Disis, M.L.; Greenwood, A.; Grad, O.; Nelson, W.G. Translational Research Working Group developmental pathway for immune response modifiers. Clin Cancer Res. 2008 Sep 15;14(18):5692-5699.
Gurel, B.; Iwata, T.; Koh, C.M.; Yegnasubramanian, S.; Nelson, W.G.; De Marzo, A.M. Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. Adv Anat Pathol. 2008 Nov;15(6):319-331.
Hawk, E.T.; Matrisian, L.M.; Nelson, W.G.; Dorfman, G.S.; Stevens, L.; Kwok, J.; Viner, J.; Hautala, J.; Grad, O. The Translational Research Working Group developmental pathways: introduction and overview. Clin Cancer Res. 2008 Sep 15;14(18):5664-5671.
Menke, A.; Guallar, E.; Shiels, M.S.; Rohrmann, S.; Basaria, S.; Rifai, N.; Nelson, W.G.; Platz, E.A. The association of urinary cadmium with sex steroid hormone concentrations in a general population sample of US adult men. BMC Public Health. 2008;8:72.
Netto, G.J.; Nakai, Y.; Nakayama, M.; Jadallah, S.; Toubaji, A.; Nonomura, N.; Albadine, R.; Hicks, J.L.; Epstein, J.I.; Yegnasubramanian, S.; Nelson, W.G.; De Marzo, A.M. Global DNA hypomethylation in intratubular germ cell neoplasia and seminoma, but not in nonseminomatous male germ cell tumors. Mod Pathol. 2008 Nov;21(11):1337-1344.
Schilsky, R.L.; Gordon, G.; Gilmer, T.M.; Courtneidge, S.A.; Matrisian, L.M.; Grad, O.; Nelson, W.G. The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics). Clin Cancer Res. 2008 Sep 15;14(18):5685-5691.
Yegnasubramanian, S.; Haffner, M.C.; Zhang, Y.; Gurel, B.; Cornish, T.C.; Wu, Z.; Irizarry, R.A.; Morgan, J.; Hicks, J.; DeWeese, T.L.; Isaacs, W.B.; Bova, G.S.; De Marzo, A.M.; Nelson, W.G. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 2008 Nov 1;68(21):8954-8967.
Zhou, Q.; Agoston, A.T.; Atadja, P.; Nelson, W.G.; Davidson, N.E. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res. 2008 May;6(5):873-883.
Antonarakis, E.S.; Heath, E.I.; Walczak, J.R.; Nelson, W.G.; Fedor, H.; De Marzo, A.M.; Zahurak, M.L.; Piantadosi, S.; Dannenberg, A.J.; Gurganus, R.T.; Baker, S.D.; Parnes, H.L.; DeWeese, T.L.; Partin, A.W.; Carducci, M.A. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol. 2009 Oct 20;27(30):4986-4993.
Bardia, A.; Platz, E.A.; Yegnasubramanian, S.; De Marzo, A.M.; Nelson, W.G. Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Current opinion in pharmacology. 2009 Aug;9(4):419-426.
Gamper, C.J.; Agoston, A.T.; Nelson, W.G.; Powell, J.D. Identification of DNA methyltransferase 3a as a T cell receptor-induced regulator of Th1 and Th2 differentiation. J Immunol. 2009 Aug 15;183(4):2267-2276.
Hansel, D.E.; Nakayama, M.; Luo, J.; Abukhdeir, A.M.; Park, B.H.; Bieberich, C.J.; Hicks, J.L.; Eisenberger, M.; Nelson, W.G.; Mostwin, J.L.; De Marzo, A.M. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate. 2009 May 1;69(6):603-609.
Liu, W.; Laitinen, S.; Khan, S.; Vihinen, M.; Kowalski, J.; Yu, G.; Chen, L.; Ewing, C.M.; Eisenberger, M.A.; Carducci, M.A.; Nelson, W.G.; Yegnasubramanian, S.; Luo, J.; Wang, Y.; Xu, J.; Isaacs, W.B.; Visakorpi, T.; Bova, G.S. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009 May;15(5):559-565.
Nelson, W.G.; De Marzo, A.M.; Yegnasubramanian, S. Epigenetic alterations in human prostate cancers. Endocrinology. 2009 Sep;150(9):3991-4002.
Paller, C.J.; Shiels, M.S.; Rohrmann, S.; Basaria, S.; Rifai, N.; Nelson, W.; Platz, E.A.; Dobs, A. Relationship of sex steroid hormones with bone mineral density (BMD) in a nationally representative sample of men. Clinical endocrinology. 2009 Jan;70(1):26-34.
De Marzo, A.M.; Nelson, W.G.; Bieberich, C.J.; Yegnasubramanian, S. Prostate cancer: New answers prompt new questions regarding cell of origin. Nat Rev Urol. 2010 Dec;7(12):650-652.
Haffner, M.C.; Aryee, M.J.; Toubaji, A.; Esopi, D.M.; Albadine, R.; Gurel, B.; Isaacs, W.B.; Bova, G.S.; Liu, W.; Xu, J.; Meeker, A.K.; Netto, G.; De Marzo, A.M.; Nelson, W.G.; Yegnasubramanian, S. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet. 2010 Aug;42(8):668-675.
Iwata, T.; Schultz, D.; Hicks, J.; Hubbard, G.K.; Mutton, L.N.; Lotan, T.L.; Bethel, C.; Lotz, M.T.; Yegnasubramanian, S.; Nelson, W.G.; Dang, C.V.; Xu, M.; Anele, U.; Koh, C.M.; Bieberich, C.J.; De Marzo, A.M. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One. 2010;5(2):e9427.
Menke, A.; Guallar, E.; Rohrmann, S.; Nelson, W.G.; Rifai, N.; Kanarek, N.; Feinleib, M.; Michos, E.D.; Dobs, A.; Platz, E.A. Sex steroid hormone concentrations and risk of death in US men. Am J Epidemiol. 2010 Mar 1;171(5):583-592.
Lin, J.; Haffner, M.C.; Zhang, Y.; Lee, B.H.; Brennen, W.N.; Britton, J.; Kachhap, S.K.; Shim, J.S.; Liu, J.O.; Nelson, W.G.; Yegnasubramanian, S.; Carducci, M.A. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate. 2011 Mar 1;71(4):333-343.
Nelson, W.G.; Saad, F.; Debruyne, F.; Eisenberger, M.; Fourcade, R.; Frenkel, E.; Kantoff, P.; Kumon, H.; Nasu, Y.; Oudard, S.; Wirth, M. New Therapeutic Targets and Treatments for Metastatic Prostate Cancer. Prostate Cancer. Paris: Health Publications; 2006.
Palapattu, G.S.; Meeker, A.; Harris, T.; Collector, M.I.; Sharkis, S.J.; DeMarzo, A.M.; Warlick, C.; Drake, C.G.; Nelson, W.G. Epithelial architectural destruction is necessary for bone marrow derived cell contribution to regenerating prostate epithelium. J Urol. 2006 Aug;176(2):813-818.
Rogers, C.G.; Gonzalgo, M.L.; Yan, G.; Bastian, P.J.; Chan, D.Y.; Nelson, W.G.; Pavlovich, C.P. High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection. J Urol. 2006 Nov;176(5):2280-2284.
Simons, J.W.; Carducci, M.A.; Mikhak, B.; Lim, M.; Biedrzycki, B.; Borellini, F.; Clift, S.M.; Hege, K.M.; Ando, D.G.; Piantadosi, S.; Mulligan, R.; Nelson, W.G. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3394-3401.
Sutcliffe, S.; Zenilman, J.M.; Ghanem, K.G.; Jadack, R.A.; Sokoll, L.J.; Elliott, D.J.; Nelson, W.G.; De Marzo, A.M.; Cole, S.R.; Isaacs, W.B.; Platz, E.A. Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. J Urol. 2006 May;175(5):1937-1942.
Yegnasubramanian, S.; Lin, X.; Haffner, M.C.; DeMarzo, A.M.; Nelson, W.G. Combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylation. Nucleic Acids Res. 2006;34(3):e19.
Agoston, A.T.; Argani, P.; De Marzo, A.M.; Hicks, J.L.; Nelson, W.G. Retinoblastoma pathway dysregulation causes DNA methyltransferase 1 overexpression in cancer via MAD2-mediated inhibition of the anaphase-promoting complex. Am J Pathol. 2007 May;170(5):1585-1593.
Bastian, P.J.; Palapattu, G.S.; Yegnasubramanian, S.; Lin, X.; Rogers, C.G.; Mangold, L.A.; Trock, B.; Eisenberger, M.; Partin, A.W.; Nelson, W.G. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5361-5367.
De Marzo, A.M.; Nakai, Y.; Nelson, W.G. Inflammation, atrophy, and prostate carcinogenesis. Urol Oncol. 2007 Sep-Oct;25(5):398-400.
De Marzo, A.M.; Platz, E.A.; Sutcliffe, S.; Xu, J.; Gronberg, H.; Drake, C.G.; Nakai, Y.; Isaacs, W.B.; Nelson, W.G. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007 Apr;7(4):256-269.
Nakai, Y.; Nelson, W.G.; De Marzo, A.M. The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. Cancer Res. 2007 Feb 1;67(3):1378-1384.
Nelson, W.G. Prostate cancer prevention. Curr Opin Urol. 2007 May;17(3):157-167.
Nelson, W.G.; Yegnasubramanian, S.; Agoston, A.T.; Bastian, P.J.; Lee, B.H.; Nakayama, M.; De Marzo, A.M. Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci. 2007;12:4254-4266.
Rohrmann, S.; Nelson, W.G.; Rifai, N.; Brown, T.R.; Dobs, A.; Kanarek, N.; Yager, J.D.; Platz, E.A. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab. 2007 Jul;92(7):2519-2525.
Rohrmann, S.; Nelson, W.G.; Rifai, N.; Kanarek, N.; Basaria, S.; Tsilidis, K.K.; Smit, E.; Giovannucci, E.; Platz, E.A. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III). Urology. 2007 Apr;69(4):708-713.
Selvin, E.; Feinleib, M.; Zhang, L.; Rohrmann, S.; Rifai, N.; Nelson, W.G.; Dobs, A.; Basaria, S.; Golden, S.H.; Platz, E.A. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care. 2007 Feb;30(2):234-238.
Small, E.J.; Sacks, N.; Nemunaitis, J.; Urba, W.J.; Dula, E.; Centeno, A.S.; Nelson, W.G.; Ando, D.; Howard, C.; Borellini, F.; Nguyen, M.; Hege, K.; Simons, J.W. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res. 2007 Jul 1;13(13):3883-3891.
Sutcliffe, S.; Rohrmann, S.; Giovannucci, E.; Nelson, K.E.; De Marzo, A.M.; Isaacs, W.B.; Nelson, W.G.; Platz, E.A. Viral infections and lower urinary tract symptoms in the third national health and nutrition examination survey. J Urol. 2007 Nov;178(5):2181-2185.
Bastian, P.J.; Ellinger, J.; von Rucker, A.; Muller, S.C.; Yegnasubramanian, S.; Nelson, W.G.; Stief, C.G. [CpG island hypermethylation of the DNA. Perspectives of a molecular biomarker for prostate cancer]. Der Urologe Ausg. 2008 Sep;47(9):1205-1207.
Bastian, P.J.; Palapattu, G.S.; Yegnasubramanian, S.; Rogers, C.G.; Lin, X.; Mangold, L.A.; Trock, B.; Eisenberger, M.A.; Partin, A.W.; Nelson, W.G. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol. 2008 Feb;179(2):529-534; discussion 534-525.
Cheever, M.A.; Schlom, J.; Weiner, L.M.; Lyerly, H.K.; Disis, M.L.; Greenwood, A.; Grad, O.; Nelson, W.G. Translational Research Working Group developmental pathway for immune response modifiers. Clin Cancer Res. 2008 Sep 15;14(18):5692-5699.
Gurel, B.; Iwata, T.; Koh, C.M.; Yegnasubramanian, S.; Nelson, W.G.; De Marzo, A.M. Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. Adv Anat Pathol. 2008 Nov;15(6):319-331.
Hawk, E.T.; Matrisian, L.M.; Nelson, W.G.; Dorfman, G.S.; Stevens, L.; Kwok, J.; Viner, J.; Hautala, J.; Grad, O. The Translational Research Working Group developmental pathways: introduction and overview. Clin Cancer Res. 2008 Sep 15;14(18):5664-5671.
Menke, A.; Guallar, E.; Shiels, M.S.; Rohrmann, S.; Basaria, S.; Rifai, N.; Nelson, W.G.; Platz, E.A. The association of urinary cadmium with sex steroid hormone concentrations in a general population sample of US adult men. BMC Public Health. 2008;8:72.
Netto, G.J.; Nakai, Y.; Nakayama, M.; Jadallah, S.; Toubaji, A.; Nonomura, N.; Albadine, R.; Hicks, J.L.; Epstein, J.I.; Yegnasubramanian, S.; Nelson, W.G.; De Marzo, A.M. Global DNA hypomethylation in intratubular germ cell neoplasia and seminoma, but not in nonseminomatous male germ cell tumors. Mod Pathol. 2008 Nov;21(11):1337-1344.
Schilsky, R.L.; Gordon, G.; Gilmer, T.M.; Courtneidge, S.A.; Matrisian, L.M.; Grad, O.; Nelson, W.G. The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics). Clin Cancer Res. 2008 Sep 15;14(18):5685-5691.
Yegnasubramanian, S.; Haffner, M.C.; Zhang, Y.; Gurel, B.; Cornish, T.C.; Wu, Z.; Irizarry, R.A.; Morgan, J.; Hicks, J.; DeWeese, T.L.; Isaacs, W.B.; Bova, G.S.; De Marzo, A.M.; Nelson, W.G. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 2008 Nov 1;68(21):8954-8967.
Zhou, Q.; Agoston, A.T.; Atadja, P.; Nelson, W.G.; Davidson, N.E. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res. 2008 May;6(5):873-883.
Antonarakis, E.S.; Heath, E.I.; Walczak, J.R.; Nelson, W.G.; Fedor, H.; De Marzo, A.M.; Zahurak, M.L.; Piantadosi, S.; Dannenberg, A.J.; Gurganus, R.T.; Baker, S.D.; Parnes, H.L.; DeWeese, T.L.; Partin, A.W.; Carducci, M.A. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol. 2009 Oct 20;27(30):4986-4993.
Bardia, A.; Platz, E.A.; Yegnasubramanian, S.; De Marzo, A.M.; Nelson, W.G. Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Current opinion in pharmacology. 2009 Aug;9(4):419-426.
Gamper, C.J.; Agoston, A.T.; Nelson, W.G.; Powell, J.D. Identification of DNA methyltransferase 3a as a T cell receptor-induced regulator of Th1 and Th2 differentiation. J Immunol. 2009 Aug 15;183(4):2267-2276.
Hansel, D.E.; Nakayama, M.; Luo, J.; Abukhdeir, A.M.; Park, B.H.; Bieberich, C.J.; Hicks, J.L.; Eisenberger, M.; Nelson, W.G.; Mostwin, J.L.; De Marzo, A.M. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate. 2009 May 1;69(6):603-609.
Liu, W.; Laitinen, S.; Khan, S.; Vihinen, M.; Kowalski, J.; Yu, G.; Chen, L.; Ewing, C.M.; Eisenberger, M.A.; Carducci, M.A.; Nelson, W.G.; Yegnasubramanian, S.; Luo, J.; Wang, Y.; Xu, J.; Isaacs, W.B.; Visakorpi, T.; Bova, G.S. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009 May;15(5):559-565.
Nelson, W.G.; De Marzo, A.M.; Yegnasubramanian, S. Epigenetic alterations in human prostate cancers. Endocrinology. 2009 Sep;150(9):3991-4002.
Paller, C.J.; Shiels, M.S.; Rohrmann, S.; Basaria, S.; Rifai, N.; Nelson, W.; Platz, E.A.; Dobs, A. Relationship of sex steroid hormones with bone mineral density (BMD) in a nationally representative sample of men. Clinical endocrinology. 2009 Jan;70(1):26-34.
De Marzo, A.M.; Nelson, W.G.; Bieberich, C.J.; Yegnasubramanian, S. Prostate cancer: New answers prompt new questions regarding cell of origin. Nat Rev Urol. 2010 Dec;7(12):650-652.
Haffner, M.C.; Aryee, M.J.; Toubaji, A.; Esopi, D.M.; Albadine, R.; Gurel, B.; Isaacs, W.B.; Bova, G.S.; Liu, W.; Xu, J.; Meeker, A.K.; Netto, G.; De Marzo, A.M.; Nelson, W.G.; Yegnasubramanian, S. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet. 2010 Aug;42(8):668-675.
Iwata, T.; Schultz, D.; Hicks, J.; Hubbard, G.K.; Mutton, L.N.; Lotan, T.L.; Bethel, C.; Lotz, M.T.; Yegnasubramanian, S.; Nelson, W.G.; Dang, C.V.; Xu, M.; Anele, U.; Koh, C.M.; Bieberich, C.J.; De Marzo, A.M. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One. 2010;5(2):e9427.
Menke, A.; Guallar, E.; Rohrmann, S.; Nelson, W.G.; Rifai, N.; Kanarek, N.; Feinleib, M.; Michos, E.D.; Dobs, A.; Platz, E.A. Sex steroid hormone concentrations and risk of death in US men. Am J Epidemiol. 2010 Mar 1;171(5):583-592.
Lin, J.; Haffner, M.C.; Zhang, Y.; Lee, B.H.; Brennen, W.N.; Britton, J.; Kachhap, S.K.; Shim, J.S.; Liu, J.O.; Nelson, W.G.; Yegnasubramanian, S.; Carducci, M.A. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate. 2011 Mar 1;71(4):333-343.
Research Interests
- prostate cancer and other urologic cancers
- new drug development
More Info
Languages
- English
Clinical Trials
- prostate cancer
Additional Resources
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts